Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|September 6, 2016

Syngene International Establishes R&D Center for Amgen

The company established a dedicated research center in Bangalore, India for Amgen.

On September 6, 2016, Syngene International, a contract research organization based in Asia, announced that it has established a multi-disciplinary drug discovery and development center for Amgen in Bangalore, India. The center is named Syngene Amgen Research and Development Center (SARC) and is Syngene’s fourth exclusive R&D center. The company currently operates facilities for Bristol-Myers Squibb, Abbott Nutrition, and Baxter.

The center will be staffed by more than 100 Syngene scientists, working in close association with Amgen researchers. The center is customized to meet Amgen’s functional requirements and is configured to minimize solvent and effluent waste.

Syngene has partnered with Amgen in a variety of discovery and development projects. With the establishment of SARC, this association now extends into a multi-discipline collaboration, spanning capabilities in medicinal and process chemistry, biologics, bioprocess, drug metabolism, pharmacokinetics, bioanalytical research, and pharmaceutical development.

Source: Syngene International


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.